{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=109",
    "query": {
      "intervention": "Protein Control",
      "page": 109
    },
    "page_size": 10
  },
  "pagination": {
    "page": 109,
    "page_size": 10,
    "total_count": 3500,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=110&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=108&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T12:13:38.144Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00634166",
      "title": "Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Sulfamylon® For 5 % Topical Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical Antimicrobial/Antifungal Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Months and older"
      },
      "enrollment_count": 220,
      "start_date": "2007-09",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2022-09-29",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 9,
      "location_summary": "Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634166"
    },
    {
      "nct_id": "NCT00069095",
      "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin 130 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine 1000 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab 7.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for bevacizumab 7.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin 85 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin 200 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil 400 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab 5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for bevacizumab 5 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2035,
      "start_date": "2003-07",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-06",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 49,
      "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Gilroy",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069095"
    },
    {
      "nct_id": "NCT01017731",
      "title": "Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "IMC-1121B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2009-11",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-06-10",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017731"
    },
    {
      "nct_id": "NCT05270837",
      "title": "Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Phenylketonuria (PKU)"
      ],
      "interventions": [
        {
          "name": "Pegvaliase",
          "type": "DRUG"
        },
        {
          "name": "Diet Only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2022-06-17",
      "completion_date": "2027-10",
      "has_results": true,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05270837"
    },
    {
      "nct_id": "NCT01423539",
      "title": "A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "navitoclax",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-10",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 13,
      "location_summary": "Fountain Valley, California • Hudson, Florida • Lawrenceville, Georgia + 10 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Centralia",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01423539"
    },
    {
      "nct_id": "NCT06962280",
      "title": "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 465,
      "start_date": "2025-05-12",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 18,
      "location_summary": "Bonita, California • Escondido, California • Newport Beach, California + 15 more",
      "locations": [
        {
          "city": "Bonita",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06962280"
    },
    {
      "nct_id": "NCT00046527",
      "title": "Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Metastases, Neoplasm"
      ],
      "interventions": [
        {
          "name": "ABI-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2001-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-13",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046527"
    },
    {
      "nct_id": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Indolent Non-Hodgkin's Lymphomas"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 295,
      "start_date": "2013-01-16",
      "completion_date": "2016-05-18",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732913"
    },
    {
      "nct_id": "NCT00760474",
      "title": "An fMRI Study Of Brain Response In Patients With Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Pregabalin, then placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo, then pregabalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2009-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00760474"
    },
    {
      "nct_id": "NCT06216886",
      "title": "OnabotulinumtoxinA for Trigeminal Neuralgia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Trigeminal Neuralgia"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 100 UNT [Botox]",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9% for Injection, Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-06-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-11-09T12:13:38.144Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216886"
    }
  ]
}